Company: LCTX
Filing Date: 2025-07-02
Form Type: 8-K
Source: 0000950170-25-093007
Chunk: 3

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-07-02
Form: 8-K
Item: Item 9.01
Chunk 3
---
Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

  Exhibit No.      Description                                                                        
 ──────────────────────────────────────────────────────────────────────────────────────────────────────
  10.1*            Amendment No. 2 to the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan  
  104              Cover Page Interactive Data File (embedded within the Inline XBRL document)        

* Incorporated by reference from Appendix A to the Proxy Statement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                           Lineage Cell Therapeutics, Inc.          
  Date:      July 2, 2025      By:         /s/ George A. Samuel III                 
                               Name:       George A. Samuel III